The case for & against
Bull & Bear analysis
Bullish
NeurAxis, Inc. (NASDAQ: NRXS) is an emerging biotechnology company specializing in innovative neuromodulation therapies, particularly focusing on its IB-Stim devices for pediatric patients suffering from functional abdominal pain. The firm is positioned to capture growth through expanding payer coverage and reimbursement policies, making it a significant player in the neuromodulation healthcare market. They are benefiting from a broader acceptance of pain management solutions and increased efforts in securing commercial payer agreements.
Bull says
- ↑Q2 revenue rose 116% YoY to $1.9M, driven by reimbursement gains
- ↑Average selling price climbed 28% to $992, boosting device pricing
- ↑Gross margin expanded to 85.9%, improving profitability profile
- ↑Expanded payer coverage triggered a 6.4% stock rally, easing cash burn
- ↑12-month price target of $13 implies 104% upside potential
- ↑High earnings yield, strong momentum and solid liquidity factors underpin resilience
Bear says
- ↓Net loss widened to $2.1M in Q2, sustaining high cash burn
- ↓Negative earnings yield and low growth factors signal valuation risks
- ↓Weak profitability metrics extend path to sustainable breakeven
- ↓Dependence on payer policies poses regulatory and reimbursement uncertainties
- ↓Analysts’ consensus revisions are negative, raising execution concerns
- ↓High growth expectations risk multiple compression on any earnings miss
Earnings Call · Q4 2023 · Mgmt. Guidance
Updated 03-23-2025bullish
Transcript signals
Bull points
- We were able to complete the remainder of the 14 studies which showed the medical community the true effectiveness of our technology and laid the foundation for the insurance coverage that we are achieving.
- Most importantly, we continue to make strides toward profitability with these investments behind us.
- Our recent successes in obtaining substantially more insurance coverage since December keeps us on that path.
Bear points
- Revenues for fiscal year 2023 of $2.5 million were down 8.4% from $2.7 million in fiscal year 2022, while the company was focused on its clinical results.
- The company's net loss in fiscal year 2023 was $14.6 million versus $4.8 million in fiscal year 2022, primarily due to higher G&A, the full amortization of the debt discount, and a $3.6 million loss on the extinguishment of debt.
- Cash used by operations of $6.7 million was substantially less than our net loss of $14.6 million, primarily due to the $4.9 million non-cash debt discount charge and the $3.6 million non-cash debt extinguishment charge.
Read full transcript analysis ›